{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:57:04Z","timestamp":1781924224189,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA052454-03, R33DA053592"],"award-info":[{"award-number":["R01 DA052454-03, R33DA053592"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Stimulant use disorder (StUD) and attention-deficit\/hyperactivity disorder (ADHD) frequently co-occur. This comorbidity complicates treatment and worsens clinical outcomes. Despite the high prevalence, shared vulnerability and clinical relevance of this comorbidity, evidence on effective pharmacotherapies among individuals with this dual diagnosis remains limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This systematic review protocol is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement and will include randomized controlled trials involving adults with comorbid StUD (cocaine, amphetamines, or methamphetamines) and ADHD. The following databases will be searched: PubMed, Embase, Scopus, and Web of Science. <jats:italic>Covidence<\/jats:italic> will be used to support independent screening and data extraction. Two reviewers will independently screen studies (title\/abstract and full text). One author will extract data, which will be independently verified by a second reviewer. Quality assessment of included articles will be assessed using the Cochrane Risk of Bias instrument, and certainty of the evidence for each outcome will be assessed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology. Primary outcomes include duration of continuous abstinence, odds of stimulant-negative urine samples, ADHD symptom changes, and medication adverse events. Where feasible, meta-analyses will be conducted using random-effects models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance and dissemination<\/jats:title><jats:p>This review will synthesize existing evidence on the efficacy of pharmacotherapies (stimulants and non-stimulants) for individuals with co-occurring StUD and ADHD. The results of this study will likely inform clinical practice by evaluating outcomes such as reduction in stimulant use and abstinence, and improvement in ADHD symptoms. Findings will be disseminated through peer-reviewed publication and presentations to reach both clinical and academic audiences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>PROSPERO, CRD420250655356.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1667614","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T10:43:49Z","timestamp":1756982629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacotherapies for stimulant use disorder and co-occurring attention deficit hyperactivity disorder: protocol for a systematic review and a meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Henrique N. P.","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Pulido-Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisson","family":"Paredes-Naveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Forselius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N.","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwole O.","family":"Jegede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A.","family":"Angarita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20021275","article-title":"Prevalence of attention deficit hyperactivity disorder (ADHD) among substance use disorder (SUD) populations: meta-analysis","volume":"20","author":"Rohner","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2013.08.010","article-title":"Attention-deficit\/hyperactivity disorder among chronic methamphetamine users: Frequency, persistence, and adverse effects on everyday functioning","volume":"38","author":"Obermeit","year":"2013","journal-title":"Addictive Behav"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2009.03.019","article-title":"Features and prevalence of patients with probable adult attention deficit hyperactivity disorder who request treatment for cocaine use disorders","volume":"185","author":"P\u00e9rez de Los Cobos","year":"2011","journal-title":"Psychiatry Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.11.04009","article-title":"The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis","volume":"11","author":"Song","year":"2021","journal-title":"J Glob Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.111.1.179","article-title":"Does stimulant therapy of attention-deficit\/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature","volume":"111","author":"Wilens","year":"2003","journal-title":"Pediatrics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13598","article-title":"Pharmacotherapy for attention-deficit\/hyperactivity disorder and retention in outpatient substance use disorder treatment: A retrospective cohort study","volume":"82","author":"Kast","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2004.03.041","article-title":"Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community","volume":"29","author":"Levin","year":"2004","journal-title":"Addict Behav"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.11.021","article-title":"Prevalence of cocaine use and cocaine use disorder among adult patients with attention-deficit\/hyperactivity disorder: A systematic review and meta-analysis","volume":"143","author":"Oliva","year":"2021","journal-title":"J Psychiatr Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3810\/pgm.2014.09.2801","article-title":"The potential for misuse and abuse of medications in ADHD: a review","volume":"126","author":"Clemow","year":"2014","journal-title":"Postgrad Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.3985","article-title":"Treatment outcomes with licensed and unlicensed stimulant doses for adults with attention-deficit\/hyperactivity disorder: A systematic review and meta-analysis","volume":"81","author":"Farhat","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1931684","article-title":"Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders","volume":"22","author":"Angarita","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-022-00432-9","article-title":"Helpful or harmful? The therapeutic potential of medications with varying degrees of abuse liability in the treatment of substance use disorders","volume":"9","author":"Martins","year":"2022","journal-title":"Curr Addict Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.0135","article-title":"Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: A systematic review and meta-analysis","volume":"74","author":"Ashok","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.2280","article-title":"Reduced GABA concentration in attention-deficit\/hyperactivity disorder","volume":"69","author":"Edden","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12402-013-0103-0","article-title":"Decreased binding capacity (Bmax) of muscarinic acetylcholine receptors in fibroblasts from boys with attention-deficit\/hyperactivity disorder (ADHD)","volume":"5","author":"Johansson","year":"2013","journal-title":"Atten Defic Hyperact Disord"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.6.832","article-title":"Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT","volume":"155","author":"Malison","year":"1998","journal-title":"Am J Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.301","article-title":"Dopaminergic system dysfunction in recreational dexamphetamine users","volume":"40","author":"Schrantee","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.58","article-title":"Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers","volume":"19","author":"Volkow","year":"2014","journal-title":"Mol Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2010.97","article-title":"Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway","volume":"16","author":"Volkow","year":"2011","journal-title":"Mol Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13123","article-title":"Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory (11) C-UCB-J positron emission tomography study in humans","volume":"27","author":"Angarita","year":"2022","journal-title":"Addict Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.1","article-title":"Impaired functional connectivity within and between frontostriatal circuits and its association with compulsive drug use and trait impulsivity in cocaine addiction","volume":"72","author":"Hu","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02519-3","article-title":"Substance use and spine density: a systematic review and meta-analysis of preclinical studies","volume":"29","author":"Oliva","year":"2024","journal-title":"Mol Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1266770","article-title":"Lower cortical thickness and increased brain aging in adults with cocaine use disorder","volume":"14","author":"Schinz","year":"2023","journal-title":"Front Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/brain.2022.0076","article-title":"Neurobiological dysfunctional substrates for the self-medication hypothesis in adult individuals with attention-deficit hyperactivity disorder and cocaine use disorder: A fluorine-18-fluorodeoxyglucose positron emission tomography study","volume":"13","author":"Carli","year":"2023","journal-title":"Brain Connectivity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3109\/10673229709030550","article-title":"The self-medication hypothesis of substance use disorders: a reconsideration and recent applications","volume":"4","author":"Khantzian","year":"1997","journal-title":"Harv Rev Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2013.12086.x","article-title":"The self-medication hypothesis and psychostimulant treatment of cocaine dependence: an update","volume":"23","author":"Mariani","year":"2014","journal-title":"Am J Addict"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05074-8","article-title":"Pharmacotherapy for cocaine use disorder-a systematic review and meta-analysis","volume":"34","author":"Chan","year":"2019","journal-title":"J Gen Intern Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.05.032","article-title":"Extended-release mixed amphetamine salts and topiramate for cocaine dependence: A randomized controlled trial","volume":"72","author":"Mariani","year":"2012","journal-title":"Biol Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/fbp.0000000000000268","article-title":"Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment","volume":"28","author":"Moran","year":"2017","journal-title":"Behav Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B32","volume-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach","author":"Sch\u00fcnemann","year":"2013"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1667614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T10:43:50Z","timestamp":1756982630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1667614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":32,"alternative-id":["10.3389\/fpsyt.2025.1667614"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1667614","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1667614"}}